We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice

Cookies settings I agree Je refuse

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:

Statistique

Nous utilisons des outils, tels que Google Analytics, pour suivre le trafic Web et vérifier l'efficacité de notre site.

Necessary

Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h

Press Releases

Bioxodes to present at Biotech Showcase™ 2023

Bioxodes to present at Biotech Showcase™ 2023
Press Releases
Bioxodes to present at Biotech Showcase™ 2023

Bioxodes to present at Biotech Showcase™ 2023 about its breakthrough drug candidate Ir-CPI for the prevention of thrombosis and neuroinflammation in hemorrhagic stroke patients.

Gosselies, Belgium, December 15th, 2022

Bioxodes a clinical-stage biotechnology company announces today that Bioxodes’ CEO, Marc Dechamps, will present a corporate overview at Biotech Showcase™ on Tuesday, January 10, 2023, at 11:30 am PST. The Biotech Showcase Conference is taking place in San Francisco in parallel to the J.P. Morgan (JPM) 41st Annual HealthCare Conference. Bioxodes will be available to meet potential partners, collaborators, and investors. Meetings can be requested through the Biotech Showcase partnering platform or by contacting Bioxodes at info@bioxodes.com.

About Bioxodes

Bioxodes specializes in the development of novel therapies for the prevention and treatment of thrombotic and inflammatory diseases. Since it was founded in 2013, Bioxodes has developed its own flagship program based around its Ir-CPI molecule. Ir-CPI is a first-in-class drug candidate aimed at patients with hemorrhagic stroke. The company, which is based in Gosselies in Belgium, has so far secured €22.1 million in funding from Belgian investment funds and business angels, including €8.5 million in non-dilutive funding from the Walloon region. Bioxodes holds both granted and pending patents associated with Ir-CPI in the European Union and the United States.

Company contact

Marc Dechamps, CEO info@bioxodes.com